Pfizer is by far the larger and better-established drugmaker. With a market cap of $156 billion, the pharmaceutical leader boasts a deep product portfolio across several therapeutic areas. Even with a ...
24/7 Wall St. on MSN
Pfizer vs Moderna: Only One Pharma Giant Is a Winner in the Post-Covid Era
Quick Read Pfizer (PFE) posted Q4 adjusted EPS of $0.66 beating the $0.57 consensus on $17.56B in revenue while its non-COVID ...
RNA rewards companies that can integrate biology, data science, manufacturing, and clinical development into a single adaptive engine. Pharma is moving into a new phase of competition one shaped less ...
An infectious disease expert has dismissed calls for more COVID vaccine makers to withdraw their jabs. Here’s why.
The smaller, more volatile of these two companies has higher potential for significant gains. However, that also comes with a healthy dose of risk. Choosing between these two stocks may come down to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results